Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

The use of GLP-1 receptor agonists, like semaglutide, to treat type 2 diabetes is not associated with an increased risk of ...

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 inches tall, and weighs 270 pounds. He is treating ...

The uptick in the Morepen Labs share came after the company announced that it has rolled out ‘Empamore.’ Empamore is used to ...

Morepen Laboratories surged 8.90% to Rs 46.61 after the company launched Empamore, an affordable treatment for type 2 diabetes, heart failure, and chronic kidney disease in India.

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...